利凡斯的明
臨床資料 | |
---|---|
商品名 | Exelon, Prometax, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a602009 |
核准狀況 | |
懷孕分級 |
|
給藥途徑 | By mouth, transdermal patch |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
生物利用度 | 60 to 72% |
血漿蛋白結合率 | 40% |
藥物代謝 | Liver, via pseudocholinesterase |
生物半衰期 | 1.5 hours |
排泄途徑 | 97% in urine |
識別資訊 | |
| |
CAS號 | 123441-03-2 |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.120.679 |
化學資訊 | |
化學式 | C14H22N2O2 |
摩爾質量 | 250.34 g·mol−1 |
3D模型(JSmol) | |
| |
|
利凡斯的明(英語:Rivastigmine,商品名:憶思能,Exelon等)是一種含氮有機化合物,分子式C14H22N2O2,屬於膽鹼酯酶抑制劑,用於治療輕度至中度阿茲海默症[4]。
參考文獻
- ^ Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. Therapeutic Goods Administration (TGA). 21 June 2022 [30 March 2024].
- ^ Product monograph brand safety updates. Health Canada. 7 July 2016 [1 April 2024].
- ^ Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-16]. (原始內容存檔於2023-08-03) (巴西葡萄牙語).
- ^ Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine. Therapeutic Advances in Drug Safety (SAGE Publications). March 2018, 9 (3): 171–178. PMC 5810854 . PMID 29492246. doi:10.1177/2042098617750555.